To examine the efficacy of anti-IL17A treatment in retinal pathogenesis, a 1 μL intravitreal injection containing 10 μg/mL, 25 μg/mL, or 50 μg/mL of anti-IL17A monoclonal antibody was administered to STZ-diabetic mice, 1 week after diabetes was confirmed by a 6 h fasted blood glucose (FBG) greater than 275 mg/dL (Figure 1A). The gene discussed is IL17A; the disease is diabetes mellitus.